Table 2. Univariate and multivariate analyses of prognostic factors for disease-free survival or disease-specific survival of stage I-III CRC patients in the study cohort.

Variables	Univariate analysisa			Multivariate analysis
	HR	95 % CI	P value	HR	95 % CI	P value
Disease-free survival
Age (≥ 60/< 60 years)	1.495	1.008–2.216	0.045	1.350	0.907–2.010	0.139
Sex(male/female)	1.014	0.705–1.460	0.939
Tumor location(rectum/colon)	1.141	0.793–1.642	0.478
Tumor size (≥ 5/< 5 cm)	1.025	0.707–1.487	0.895
Bowel obstruction/perforation (yes/no)	0.955	0.390–2.340	0.920
Differentiation grade (poor/well + moderate)	1.807	1.236–2.643	0.002	1.402	0.949–2.070	0.090
Local invasion (T3–T4/T1–T2)	1.074	0.675–1.708	0.764
Serum CEA level (≥ 10/ < 10 ng/mL)	1.002	0.695–1.444	0.991
TNM stage (III/I + II)	2.098	1.451–3.034	< 0.001	1.933	1.331–2.807	0.001
PRDX2 expression (high/low)	2.575	1.724–3.845	< 0.001	2.322	1.536–3.509	< 0.001
Disease-specific survival
Age (≥ 60/< 60 years)	1.752	1.096–2.801	0.019	1.652	1.030–2.649	0.037
Sex (male/female)	1.014	0.668–1.540	0.948
Tumor location (colon/rectum)	1.084	0.714–1.647	0.704
Tumor size (≥ 5/< 5 cm)	0.852	0.559–1.299	0.457
Bowel obstruction/perforation (yes/no)	0.978	0.359–2.668	0.966
Differentiation grade (poor/well + moderate)	2.019	1.316–3.097	0.001	1.671	1.079–2.589	0.022
Local invasion (T3–T4/T1–T2)	1.229	0.705–2.142	0.468
Serum CEA level (≥ 10/ < 10 ng/mL)	1.017	0.668–1.547	0.939
TNM stage (III/I + II)	1.809	1.186–2.760	0.006	1.578	1.030–2.417	0.036
PRDX2 expression (high/low)	2.388	1.502–3.798	< 0.001	2.046	1.270–3.296	0.003

Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; PRDX2, peroxiredoxin 2; TNM, tumor-node-metastasis.

^a In univariate analyses, log-rank tests were conducted.

^b In the multivariate Cox proportional hazard model, only variables with P < 0.05 in univariate analysis were included and the “enter method” was applied.